Citation Impact
Citing Papers
Transcriptional Profiling of the Human Monocyte-to-Macrophage Differentiation and Polarization: New Molecules and Patterns of Gene Expression
2006 Standout
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
2017 Standout
From XenoMouse technology to panitumumab, the first fully human antibody product from transgenic mice
2007
Adalimumab for Maintenance of Clinical Response and Remission in Patients With Crohn’s Disease: The CHARM Trial
2006 Standout
Infliximab for the Treatment of Fistulas in Patients with Crohn's Disease
1999 Standout
Improving Chimeric Antigen Receptor-Modified T Cell Function by Reversing the Immunosuppressive Tumor Microenvironment of Pancreatic Cancer
2017
Pulmonary fibrosis: pathogenesis, etiology and regulation
2009 Standout
Inflammatory bowel disease: clinical aspects and established and evolving therapies
2007 Standout
Thalidomide therapy for patients with refractory Crohn's disease: An open-label trial
1999
Poor clinical outcome of patients with Hodgkin's Disease and elevated interleukin-10 serum levels
2000
Inflammatory Bowel Disease
2002 Standout
Reduced Th1 response in the lungs of HLA-DRB1*0301 patients with pulmonary sarcoidosis
2006
Hodgkin's Lymphoma Cell Lines Express a Fusion Protein Encoded by Intergenically Spliced mRNA for the Multilectin Receptor DEC-205 (CD205) and a Novel C-type Lectin Receptor DCL-1
2003
CAR-T cell therapy: current limitations and potential strategies
2021 Standout
Development of therapeutic antibodies for the treatment of diseases
2020 Standout
Cancer and the chemokine network
2004 Standout
Tumour necrosis factor and Crohn's disease.
1997
Sarcoidosis
2007 Standout
Molecular biology and targeted therapies for urothelial carcinoma
2015
A Novel Chimeric Antigen Receptor Against Prostate Stem Cell Antigen Mediates Tumor Destruction in a Humanized Mouse Model of Pancreatic Cancer
2014
Immunology of Tuberculosis
2001 Standout
Molecular Pathogenesis of Hodgkin's Lymphoma
2005
Natural Products as Sources of New Drugs over the Nearly Four Decades from 01/1981 to 09/2019
2020 Standout
The AP1-dependent secretion of galectin-1 by Reed–Sternberg cells fosters immune privilege in classical Hodgkin lymphoma
2007 Standout
Impact of Drug Conjugation on Pharmacokinetics and Tissue Distribution of Anti-STEAP1 Antibody–Drug Conjugates in Rats
2011
Increased inflammatory cytokines and new collagen formation in cutaneous tuberculosis and sarcoidosis.
1996
Bladder Cancer
2020 Standout
Anti-TNF Therapy in Crohn’s Disease
2018
Marine-Sourced Anti-Cancer and Cancer Pain Control Agents in Clinical and Late Preclinical Development
2014
In Situ Production of Gamma Interferon, Interleukin-4, and Tumor Necrosis Factor Alpha mRNA in Human Lung Tuberculous Granulomas
2000
Alternative Activation of Macrophages: An Immunologic Functional Perspective
2008 Standout
Interleukin-10 and the Interleukin-10 Receptor
2001 Standout
Antibody-Drug Conjugates in Urothelial Carcinomas
2020
Natural product and natural product derived drugs in clinical trials
2014 Standout
Site-Specific Antibody–Drug Conjugates: The Nexus of Bioorthogonal Chemistry, Protein Engineering, and Drug Development
2014 StandoutNobel
Current Status of Marine-Derived Compounds as Warheads in Anti-Tumor Drug Candidates
2017
The role of cytokines in classical Hodgkin lymphoma
2002
The Influence of Probiotics on the Firmicutes/Bacteroidetes Ratio in the Treatment of Obesity and Inflammatory Bowel disease
2020 Standout
Works of Kendall Morrison being referenced
Development of ASG-15ME, a Novel Antibody–Drug Conjugate Targeting SLITRK6 , a New Urothelial Cancer Biomarker
2016
Global, multicenter, randomized, phase II trial of gemcitabine and gemcitabine plus AGS-1C4D4 in patients with previously untreated, metastatic pancreatic cancer
2013
Detection of tumour necrosis factor alpha in sarcoidosis and tuberculosis granulomas using in situ hybridisation.
1994
Abstract 1274: SLITRK6, the target of a novel antibody drug conjugate AGS15E, is expressed in bladder and other cancers.
2013
Abstract 2047: Discovery and molecular characterization of AGS-15/SLITRK6 as a novel target for antibody-mediated therapeutic development in bladder cancer.
2013
Monoclonal Antibodies to Six-Transmembrane Epithelial Antigen of the Prostate-1 Inhibit Intercellular Communication In vitro and Growth of Human Tumor Xenografts In vivo
2007
Interim analysis of a phase I dose escalation trial of the antibody drug conjugate (ADC) AGS15E (ASG-15ME) in patients (Pts) with metastatic urothelial cancer (mUC)
2016
Tumor necrosis factor alpha and lymphotoxin production in Hodgkin's disease.
1990
Therapeutic potential of AGS-PSCA: A fully human monoclonal antibody to prostate stem cell antigen (PSCA) for the treatment of prostate and pancreatic cancers
2005